WHO preferred product characteristics for invasive non-typhoidal Salmonella vaccines

Overview

Invasive non-typhoidal serovars of Salmonella enterica, S. Typhimurium and S. Enteritidis, (iNTS) were estimated to cause over 500 000 invasive disease illnesses associated with more than 79 000 deaths in the Institute for Health Metrics and Evaluation Global Burden of Disease Study in 2019 with a high case fatality ratio of 14.5%. Several iNTS vaccines are currently in development and could be an important new tool in the fight against invasive disease.

WHO preferred product characteristics (PPCs) provide strategic guidance as to WHO’s preferences for new vaccines in priority disease areas. PPCs are intended to encourage innovation and development of vaccines for use in settings most relevant to the global unmet public health need.  iNTS vaccine PPCs describe global public health goals and use cases for iNTS vaccines designed prevent invasive disease, and they outline preferred vaccine parameters such as vaccine indications, target populations, safety and efficacy considerations, and immunization strategies.